XOMA Royalty (XOMA) Q2 Earnings and Revenues Surpass Estimates

Company Performance - XOMA Royalty reported quarterly earnings of $0.48 per share, exceeding the Zacks Consensus Estimate of a loss of $0.12 per share, and showing improvement from a loss of $0.28 per share a year ago, resulting in an earnings surprise of +500.00% [1] - The company posted revenues of $13.13 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 39.30%, compared to revenues of $11.09 million in the same quarter last year [2] - Over the last four quarters, XOMA Royalty has surpassed consensus EPS estimates three times and has topped consensus revenue estimates three times as well [2] Stock Performance - XOMA Royalty shares have increased approximately 8.3% since the beginning of the year, while the S&P 500 has gained 9.6% [3] - The current status of estimate revisions for XOMA Royalty is mixed, leading to a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.03 on revenues of $9.75 million, and for the current fiscal year, it is $0.02 on revenues of $45.7 million [7] - The outlook for the Medical - Biomedical and Genetics industry, where XOMA Royalty operates, is currently in the bottom 41% of over 250 Zacks industries, which may impact the stock's performance [8]